|
Re: Repetitive musings on repetitive issues
|
3
|
Resverlogix Corp.
|
Feb 12, 2021 11:42PM
|
|
Re: Resverlogix Announces $13 Million Private Placement
|
6
|
Resverlogix Corp.
|
Oct 06, 2020 06:27PM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
9
|
Resverlogix Corp.
|
Aug 29, 2023 08:37AM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
3
|
Resverlogix Corp.
|
Aug 22, 2019 09:26PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
4
|
Resverlogix Corp.
|
Sep 09, 2021 02:26AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 09:30AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 10:16AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 10:39AM
|
|
Re: Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
|
3
|
Resverlogix Corp.
|
Sep 23, 2019 10:57AM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
7
|
Resverlogix Corp.
|
Jun 06, 2020 06:41PM
|
|
Re: Resverlogix Announces Loan Reduction and Extension
|
4
|
Resverlogix Corp.
|
Aug 02, 2019 01:43PM
|
|
Re: Resverlogix Announces Loan Reduction and Extension
|
3
|
Resverlogix Corp.
|
Aug 02, 2019 02:26PM
|
|
Re: Resverlogix Announces Loan Reduction and Extension
|
2
|
Resverlogix Corp.
|
Aug 05, 2019 04:48PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
14
|
Resverlogix Corp.
|
Apr 01, 2020 07:02PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
6
|
Resverlogix Corp.
|
Aug 07, 2020 02:04AM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
2
|
Resverlogix Corp.
|
Jun 22, 2022 01:27PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 27, 2020 11:05AM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 27, 2020 02:11PM
|
|
Re: Resverlogix Confirms Significant Corporate Advancement Establishing Apabetalone as Potential Blockbuster Combo Drug in High-risk Diabetics with CVD
|
4
|
Resverlogix Corp.
|
Jan 13, 2020 09:24AM
|
|
Re: Resverlogix Expands Phase 2b Clinical Trial for COVID-19
|
7
|
Resverlogix Corp.
|
Feb 17, 2022 02:43PM
|
